Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 7 Neoplasms 4 Glioblastoma 4 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rare Tumour 1 Neuroectodermal Tumors 1 Nervous System Diseases 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoadjuvant Therapy 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Locally Advanced Prostate Cancer 1 Limited Stage Small Cell Lung Cancer 1 Hereditary leiomyomatosis and renal cell cancer 1 HER2-negative Breast Cancer 1 Gliosarcoma 1 Glioma 1 For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1 Esophageal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinosarcoma 1

Interventions

tislelizumab 1 pamiparib 1 TNFeraseBiologic 1 Injections 1 Gefitinib 1 Docetaxel 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Locally Advanced Prostate Cancer × pamiparib × Clear all

NCT06387056 2024-04-26

SEGNO

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting

Locally Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡